NASDAQ | Warrant
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States.
It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -2.48 M Decreased by -1.39% | Decreased by N/A% Decreased by N/A% |
| Feb 29, 24 | 0.00 Decreased by N/A% | -2.48 M Decreased by -1.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -3.07 M Decreased by -92.18% | Decreased by N/A% Decreased by N/A% |
| Nov 30, 23 | 0.00 Decreased by N/A% | -3.07 M Decreased by -92.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -2.45 M Decreased by -19.81% | Decreased by N/A% Decreased by N/A% |
| Aug 31, 23 | 0.00 Decreased by N/A% | -2.45 M Increased by +23.44% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.60 M Increased by +50.02% | Decreased by N/A% - |
| May 31, 23 | 0.00 Decreased by N/A% | -1.60 M Increased by +52.11% | Decreased by N/A% Decreased by N/A% |